Morning Trend | GRANDPHARMA tests new lows again, can the main line rebound from the pressure of negative factors in the sector?

On January 12th, GRANDPHARMA (0512.HK) fluctuated around the HKD 8 level throughout the day, with the pharmaceutical sector recently becoming a heavy area of capital outflow, and the market continues to be under pressure. The company has no new product applications or favorable external mergers and acquisitions, resulting in a short-term "vacuum period." There were occasional surges during the trading session, but they were ultimately suppressed by short sellers, and the weak rebound could not break the pressure pattern. MACD, KDJ, and Bollinger Bands are all weakening, with a strong atmosphere of bottoming out in a sideways trend. Pharmaceutical policy regulation is tightening, and there are no significant new drugs or restructuring stimuli in the market. Mainstream capital is actively avoiding risks, and the overall sentiment is calm. Analysts believe that only a shift to looser policies or the restart of major projects will ignite a recovery market. Sudden mergers/acquisitions or drug progress during trading could signal short-term speculation; otherwise, there is sufficient downward momentum. Risk control: Pay attention to the movements of industry leaders and policy news, with a defensive approach to operations. Extreme trends may lead to a new round of declines due to capital bleeding